Market Cap | 2.36M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -2M | Forward P/E | -0.01 | EPS next Y | - | 50D Avg Chg | -25.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -59.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -88.00% |
Recommedations | - | Quick Ratio | - | Shares Outstanding | 1.24B | 52W Low Chg | 20.00% |
Insider Own | 7.45% | ROA | -1,597.98% | Shares Float | 1.15B | Beta | 1.56 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00300 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 3,022,984 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 612,581 | Change | -6.25% |
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.